Acromegaly is usually caused by a noncancerous tumor. Middle-aged adults are most commonly affected. Symptoms include enlargement of the face, hands, and feet. Prompt treatment is needed to avoid serious illness. Drugs can reduce the effects of growth hormone. If needed, surgery and radiation may be used to remove tumor cells.
Could artificial intelligence and machine learning recognize the early, subtle changes in people’s faces associated with the hormonal disease acromegaly? New research spearheaded by Dr. Manel Puig-Domingo and outlined in a recent paper published in the journal PITUITARY raises the possibility that AI algorithms and machine learning could provide a game-changing approach to the early diagnosis of this complex disease, which now takes an average of 6 to 10 years to diagnose.
In January 2021, the Acromegaly Community, a US-based patient advocacy organization, organized and participated in an externally lead patient focus drug development meeting. The EL-PFDD initiative is a Food and Drug Administration (FDA) effort to systematically
In this Podcast, Dr. Blevins gives us a perspective of the last 30 years on the developments in this field. Like many other conditions, the advances in therapy, imaging, surgery techniques, diagnostic testing, and clinical knowledge have been nothing short of remarkable.
Music Composed and Produced by, MusicWorksFoundry(TM) (ASCAP). All Rights Reserved.
Music Composed and Produced by, MusicWorksFoundry(TM) (ASCAP). All Rights Reserved.
Music Composed and Produced by, MusicWorksFoundry(TM) (ASCAP). All Rights Reserved.
From the desk of J D Faccinetti – co-founder – The company recently kicked off a phase 3 trial for their new nonpeptide oral drug for acromegaly and announced the dosing of their first acromegaly
Acromegaly: what to do with medical treatment during pregnancy and the options available today.
From Jorge D. Faccinetti – co-founder. With a pituitary disease like acromegaly, Cushing’s, hypopituitarism, and others, or for that matter, any other chronic condition, a big part of the battle is to get up every
Camurus AB, a pharmaceutical company based in Lund, Sweeden, is currently recruiting volunteers for two clinical trials on the long-term safety and efficacy of an octreotide subcutaneous depot to treat acromegaly. This new treatment offers
If you missed this fantastic event, here is an on-demand video you can watch at your leisure. In this second installment of the Ionis’ Rare Disease Webinar series, panelists discuss acromegaly, a condition in which
On Thursday, January 21, 2021, there is a virtual FDA Externally Led Patient-Focused Drug Development (PFDD) meeting organized by the Acromegaly Community, a leading patient advocacy organization in the US. To learn more about
During these trying times, work continues, even at a faster pace, for new drugs and therapies for pituitary patients. From the J D Faccinetti, co-founder – We recently caught up with Crinetics Pharmaceuticals chairman Dr.